-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $772

Benzinga·07/31/2026 13:27:28
Listen to the news
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $769 to $772.